Groningen, The Netherlands – 10 April 2025 – InnoCore Pharmaceuticals (“InnoCore”), a leading specialist in long-acting injectable (LAI) drug delivery technologies, today announced a formulation development partnership with an undisclosed North American pharmaceutical company to advance a peptide therapeutic designed to support improved metabolic and glucose-control outcomes, potentially relevant to conditions such as Type 1 diabetes.
The collaboration will leverage InnoCore’s proprietary SynBiosys® technology, a best-in-class, biodegradable polymer platform designed to enable sustained and controlled release of biologics and peptides. The new project marks the first partnership between InnoCore and the undisclosed company.
SynBiosys® overcomes the significant challenges associated with peptide formulation, such as aggregation, enzymatic degradation, and acylation, by providing a protective, tunable polymer matrix that preserves molecular integrity and ensures consistent, predictable release kinetics. The technology enables adjustable dosing intervals, from weeks to months, allowing for improved patient convenience and treatment efficacy.
This agreement represents another milestone in InnoCore’s strategic expansion of business in the peptide and biologics LAI market, an area of accelerating global demand as pharma and biotech innovators seek to improve therapeutic performance, patient adherence, and lifecycle management through sustained-release formulations.
Rob Steendam, Chief Technology Officer at InnoCore Pharmaceuticals, commented:
“We are delighted to welcome this new partner into our growing network of global collaborators who have come to InnoCore on the basis of our formulation experience and the features of our innovative technology, SynBiosys®. This project will help strengthen the strategic position of their product portfolio in an important way. Our specialisation in the field of biologics and peptides formulation, coupled with a flexible approach allows us to work effectively with partners of all sizes, from emerging biotech companies to global pharmaceutical leaders, providing tailored formulation solutions based on our decades of experience and proven technology.”
With over 20 years of expertise in polymer design, formulation development, and process optimization, InnoCore offers a complete range of services, from feasibility studies and analytical characterization to scale-up and technology transfer for GMP manufacturing. Operating from its state-of-the-art facilities in Groningen, The Netherlands, the company provides fully integrated, scientifically driven support to help partners bring complex LAI products from concept to clinic.
-Ends-
For more information, please contact:
Notes to Editors
About InnoCore Pharmaceuticals
InnoCore Pharmaceuticals is a leading drug delivery development provider, formulating peptide and biologic APIs into scalable, biodegradable and tunable Long Acting Injectable (LAI) dosage forms.
The Company’s proprietary polymeric drug delivery platform, SynBiosys®, overcomes the significant technical challenges of translating these complex and fragile molecules into LAI drug products that maintain their essential bioactive characteristics.
Dosage forms can be created for early proof of concept, through to clinical trial usage in an easy-to-scale cGMP form. These formulations can be adapted for use in local or systematic injectable forms for a wide range of therapeutic applications, such as osteoarthritis, rheumatology, oncology, CNS, infectious and cardiometabolic diseases.
InnoCore is a true strategic partner to its biopharma customers working hand-in-hand with them to lay strong foundations for future clinical and commercial success. InnoCore is innovating biologic drug formulation for better treatment outcomes and compliance.
For more information, please see: www.innocorepharma.com